LMAT
Fallen FavouriteLeMaitre Vascular, Inc. · Healthcare · United States · $1.9B cap · $23.0M/day traded
$79.29 +0.3% · close 11 Nov · scored 11 Nov
Fallen Favourite: A good business, still expensive, and its momentum is weak.
Around its 5 Nov results, analysts left next year's EPS estimate little changed.
As of 11 Nov 2026, the MoatMap Score for LeMaitre Vascular, Inc. (LMAT) is 50/100, ranked against 25,000+ stocks in 38 markets (Quality 75, Value 36, Momentum 33, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT LEMAITRE VASCULAR, INC.
Read
LeMaitre Vascular, Inc. is a global provider of medical devices for the treatment of peripheral vascular disease, designing, manufacturing, and marketing a broad portfolio of interventional and implantable devices. LeMaitre Vascular benefits from a comprehensive and specialized product portfolio addressing niche areas of peripheral vascular surgery, supported by a direct sales force. Its focus on innovative solutions for a specific disease state creates a strong competitive advantage.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 161.7M | 193.5M | 219.9M | 249.6M | 15.6% | 269.4M | 276.0M | 303.4M | 10.3% |
| EPS | 0.94 | 1.36 | 1.96 | 2.55 | 39.5% | 2.75 | 2.85 | 3.20 | 12.0% |
| Shares | 22.1M | 22.3M | 22.5M | 22.8M | +3.1% | 22.9M | — | — | — |
| Debt | 16.6M | 19.1M | 185.7M | 185.6M | 123.6% | 188.9M | — | — | — |
| Equity | 268.2M | 297.9M | 337.3M | 393.5M | 13.6% | — | — | — | — |
| Op CF | 25.4M | 36.8M | 44.1M | 81.3M | 47.4% | 76.2M | — | — | — |
| Inv CF | -10.4M | -24.7M | -200.1M | -64.9M | — | — | — | — | — |
| Fin CF | -9.2M | -7.1M | 158.1M | -14.5M | — | — | — | — | — |
No new 52-week low for 7 weeks, 1% above that low, but not back above a rising 50-day average.
Swung more than 57% of stocks we rank over the past year (volatility 46% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LMAT are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| LMAT | LeMaitre Vascular, Inc.(you) | $1.9B | 50 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 51 |
| AZTA | Azenta, Inc. | $1.6B | 45 |
| WRBY | Warby Parker Inc. | $3.2B | 54 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 29 |
| MMED | MiniMed Group, Inc. | $5.2B | 59 |
| STAA | STAAR Surgical Company | $1.1B | 31 |
| PLSE | Pulse Biosciences, Inc. | $3.8B | 28 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
Peer medians: ROE -31.0% · P/E 25.7x · Gross margin 62.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.